Aptar Pharma Launches Drug Delivery Device at CPhI Worldwide

Published on: 

The company will showcase its line of connected devices at and its new PureHale portable drug delivery device designed for upper respiratory care.

On Sept. 12, 2018, Aptar Pharma, a drug delivery systems provider, announced it will be presenting its new PureHale portable drug delivery device, at CPhI Worldwide, which will be held Oct. 9–11, 2018 in Madrid. PureHale is is designed for upper respiratory care.

The company also will be showcasing its new connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes; gamma-sterilized drug delivery components to reduce bioburden; and the company’s Support Services initiative, a portfolio of stage-specific development packages.

In addition to showcasing its product and services, Aptar Pharma executives will be delivering three Pharma Insight Briefings:

Advertisement
  • “Debunking the Leachable Myths of Gamma Sterilization: A Migration Study of Steam vs Gamma,” Julie D. Suman, RPh, PhD, president of Next Breath, a division of Aptar Pharma; Tuesday October 9, 11:50 am–12:20 pm. Julie Suman will present a migration study commissioned by Aptar Pharma to assess the impact of both steam sterilization and gamma sterilization on leachable profiles.

  • “Building a Connected Devices Eco-system for Digital Medicines,” Sai Shankar, director Business Development, Aptar Pharma; Wednesday, October 10, 13:50-14:20 pm.

“Through a wide range of consulting and services, Aptar Pharma innovates around delivery routes, effective drug delivery, testing and regulatory requirements with partners ranging from small-scale R&D firms to the largest international pharmaceutical companies. We look forward to launching our Support Services initiative at CPhI and working with our customers to meet their development needs,” said Guillaume Brouet, vice president Analytical, Regulatory and Scientific Affairs at Aptar Pharma, in a press release.

Visit Aptar Pharma at stand 4D10.

Source: Aptar Pharma